Hemostatic changes in patients with malignancy.
Alterations of hemostasis commonly accompany the progression of malignant disease and every known component of the hemostatic mechanism may be affected by this disease process. Nearly all patients with an active neoplasm will exhibit at least subtle biochemical changes in hemostasis, and a minority of these patients will also develop clinical thrombosis or hemorrhage. In this paper, we will review intravascular coagulation and fibrinolysis, thrombocytopenia, and thrombocytosis, as well as more rare thrombotic and hemorrhagic events resulting from the direct interactions of neoplasms, or of their products, with the individual elements of hemostatic mechanisms. Thrombotic and hemorrhagic events resulting from the induction of autoimmune or thrombotic microangiopathic syndromes are also discussed. This review focuses on the clinical thrombotic and bleeding syndromes that may occur as a result of this interaction between neoplasia and hemostasis.
Goldsmith
G H
GH
James Graham Brown Cancer Center, University of Louisville, Kentucky, USA.
D006470:Hemorrhage / Q000209:etiology; D006490:Hemostatics / Q000097:blood*; D006801:Humans; D009369:Neoplasms / Q000097:blood / Q000150:complications*; D013927:Thrombosis / Q000209:etiology
D006490:Hemostatics